Tendyne, the mitral valve replacement technology that Abbott Laboratories Inc. acquired three years ago, has potential to successfully treat patients with severe mitral regurgitation, according to early follow-up data presented May 23 at EuroPCR in Paris.
The results from a single-arm, multicentre global study to support the CE mark of Tendyne were presented at EuroPCR by...